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Previewshuman nodular BCCs arise from the hair
follicle bulge (Jih et al., 1999).
Other types of mouse models for basal
cell carcinoma depend on overexpression
of genes in the hedgehog pathway, such
as Gli and Smo; for example, targeting
of Gli expression to the follicle and IFE
results in the formation of basal cell
tumors that clinically resemble human
basal cell carcinomas in that they have
a translucent appearance and the pres-
ence of small vessels known as telangiec-
tasias (Grachtchouk et al., 2000; Nilsson
et al., 2000). These tumors are dependent
on continuous Gli expression and regress
if the transgene is turned off. Results of
early clinical trials suggest that human
BCCs are similarly ‘‘addicted’’ to hedge-
hog signaling and may be amenable to
targeted therapy.
Dlugosz and colleagues previously pub-
lished that constitutive overexpression of
activated Smo in the epidermis resulted
in basaloid hamartomas (Grachtchouk
et al., 2003). These investigators were
careful to distinguish between basaloid
hamartomas and BCC because basaloid
hamartomas, both in humans and in
mice, have limited growth potential and
rarely develop into BCC. In a more recent
study, Blanpain and colleagues also over-
expressedactivatedSmo in the epidermis,
but with an inducible system, and6 Cancer Cell 19, January 18, 2011 ª2011 Eldescribed the formation of ‘‘basal cell
carcinomas.’’ (Youssef et al., 2010) One
problem with both the Blanpain and the
Wang paper rests on whether the tumors
that developed are truly BCCs or whether
they are basaloid hamartomas. Input
from a dermatopathologist is essential for
making the distinction, but marker studies
would be ideal. Nonetheless, these find-
ings do suggest that non-bulge cells have
a lower threshold thanbulgecells for tumor
development in response to oncogenic
Smo.
Wang et al. suggest that loss of p53
triggers Smo expression in epidermis of
Ptch1+/mice. Since Smo is an obligatory
activator of Hh signaling, the resultant
epidermal BCCs in irradiated p53-defi-
cient Ptch1+/ mice suggests that loss of
p53 may be a primary event in BCC
formation, operating through the novel
mechanism of Smo upregulation. This
important concept deserves testing in
both human epidermis with known p53
mutations and inmousemodels. The find-
ings could impact on future targeting of
incipient BCC with chemotherapeutic
agents.REFERENCES
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In this issue of Cancer Cell, Sonoshita et al. report that Aes/Grg5 prevents metastasis of colorectal cancer
cells by sequestering and inactivating Notch transcriptional effectors in distinct nuclear foci. Loss of Aes/
Grg5 in invasive cancer cells where Notch is activated by stroma-expressed ligands promotes invasion,
transendothelial migration, intravasation, and metastasis.Metastatic disease is the major cause of
cancer-associated death. During the
metastatic process, cancer cells need to
overcome a number of hurdles, includinginvasion into neighboring tissue, intrava-
sation into blood or lymphatic vessels,
survival in the circulation, extravasation
from vessels at distant organs, and colo-nization and outgrowth at the distant
sites. Each of these events involves
a number of signaling pathways. In this
issue of Cancer Cell, Sonoshita and
Cancer Cell
Previewscoworkers (Sonoshita et al., 2011) report
that the transcriptional regulator Amino-
terminal Enhancer of Split (Aes) or its
mouse homolog Groucho gene-related
protein 5 (Grg5) represses specific steps
of the metastatic spread of colorectal
cancer cells by inhibiting Notch signaling.
Sonoshita et al. first identified Aes/Grg5
as a highly expressed gene in primary
tumors of Colon26 cancer cells trans-
planted into syngeneic Balb/c mice, yet
absent in liver and lung metastasis
derived thereof. Aes/Grg5 expression is
also found to be low in liver metastasis
of colorectal cancer patients. Notably,
cells at the invading front of transplanted
cancer cells as well as in human primary
colorectal cancers also lack Aes/Grg5
expression, and the loss significantly
correlates with tumor invasion and
progression stage. Indeed, genetic and
pharmacological gain and loss of function
experiments with transplantation models
of colon cancer demonstrate that Aes/
Grg5 efficiently suppresses cell invasion
and metastasis without affecting primary
tumor growth.
Aes/Grg5 is the smallest member of
a family of conserved non-DNA binding
transcriptional regulators, the Transdu-
cin-like Enhancer of Split (TLE) proteins
and their mouse homologs, the Grg
transcriptional regulators (Beagle and
Johnson, 2010). In contrast to the exclu-
sive transcriptional repression exerted
by the long TLEs/Grgs, Aes/Grg5 acts as
both repressor and activator of transcrip-
tion and is critical in a variety of biological
processes (Beagle and Johnson, 2010).
The TLE/Grg proteins have also been
implicated in the regulation of pathways
well known to affect tumor progression,
including the Wnt, TGFb, Hedgehog,
and Notch signaling pathways. Indeed,
Sonoshita et al. find an efficient, dose-
dependent repression of Notch signaling
by Aes/Grg5, while it only marginally
stifles Wnt signaling and has no effect on
TGFb or Hedgehog signaling. In contrast,
TLE1, another member of the TLE/Grg
family, fails to repress Notch signaling by
itself, yet it physically interacts with and
potentiates the inhibitory activities of
Aes/Grg5.
The authors go on to delineate the
mechanism by which Aes/Grg5 represses
Notch-mediated signal transduction. In
mammals, Notch signaling is activated
by binding of transmembrane ligands,such as Delta-like (Dll1-4), Serrate and
Jagged1-2, to the transmembrane Notch
receptors (Notch 1-4) (Kopan and Ilagan,
2009). Ligand binding promotes cleavage
of the Notch receptors and the release of
the Notch intracellular domain (NICD).
NICD then translocates to the nucleus
and associates with the DNA-binding
protein CSL (Rbpjk in mouse) and its
coactivators Mastermind-like (Maml1-4)
or the nuclear corepressor SMRT (Silenc-
ing Mediator for Retinoid and Thyroid
receptors) (Kopan and Ilagan, 2009).
Sonoshita et al. show that ectopically ex-
pressedGFP-Aes localizes diffusely in the
cytoplasm and the nucleoplasm. Rbpjk,
NICD, and Maml1 also showed diffuse
nucleoplasmic localization in these cells.
Coexpressing TLE1, however, resulted
in localization of GFP-Aes to distinct
nuclear foci, which also contain Rbpjk,
NICD, and Maml1. Lack of transcription
in these foci is reminiscent of the Bach2
foci or the matrix-associated deacetylase
(MAD) bodies containing histone deacety-
lases (HDAC), the Notch signaling core-
pressor SMRT, and a number of other
transcriptional regulators and chromatin
modifiers (Hoshino et al., 2007; Downes
et al., 2000). These data suggest that
Aes/Grg5 represses Notch signaling by
sequestration and inactivation of the
Notch-activated transcription complex
in distinct foci of the nuclear matrix
(Figure 1). Whether Aes/Grg5 is actively
contributing to HDAC-mediated tran-
scriptional repression warrants further
investigation.
Sonoshita et al. also address the
mechanism underlying Notch signaling
activation in cancer cells to promote
metastasis formation. In their Colon26
transplantation model, Notch receptors
are expressed on cancer cells, whereas
the ligands are found on stromal cells
(Jagged1 in endothelial cells of tumor-
associated blood vessels and Dll4 on
endothelial cells, smooth muscle cells,
and macrophages). Notch signaling
activation is mainly found in cancer
cells in the vicinity of blood vessels in
primary tumors. In metastatic lesions,
Notch-activated cells are either found in
micrometastasis or in the outer rim of
larger metastasis next to stromal cells.
Hence, Notch signaling is high in cancer
cells adjoining blood vessel and stroma,
where Aes/Grg5 is found low and where
a high number of cancer cells haveCancer Cellentered into blood vessels (intravasation;
Figure 1). In vitro transendothelial
migration (TEM) assays with endothelial
cells expressing Notch ligands and
cancer cells expressing Notch receptors
support the notion that Notch activation
by a tumor-stroma interaction is critical
for cancer cell intravasation. Knockdown
of Aes/Grg5 in the cancer cells results
in increased TEM, whereas ablation
of Rbpjk represses TEM. These data indi-
cate that Notch ligands on endothelial and
stromal cells induce Notch signaling in
cancer cells and thus promote their TEM.
Finally, the authors have generated
mice carrying conditional alleles of Aes/
Grg5 to demonstrate that the lack of
Aes/Grg5 in the intestinal epithelial tumor
cells of ApcD716 mice leads to increased
tumor invasion, abundant intravasated
cells, and tumor embolism. The marked
increase in tumor invasion is dependent
on Notch signaling, since it is repressed
by pharmacological inhibition. Interest-
ingly, despite increased invasion, no
signs of epithelial-mesenchymal transition
(EMT) and no metastasis have been
observed in these mice.
Altogether, these data show that Aes/
Grg5 is a metastasis suppressor gene,
mainly by preventing Notch signaling
and Notch-mediated local invasion and
intravasation. Thus, Notch appears to
contribute to the early stages of the meta-
static process but does not affect primary
tumor growth or metastatic outgrowth per
se (Sonoshita et al., 2011). On the other
hand, Notch is known to modulate
cell apoptosis, survival, differentiation,
and EMT. The reason for the conflicting
observations may lie in the variety of
cancer types studied or in the genetic
context of the cancer cells used in the
studies. Notably, Colon26 cells carry
a Ras mutation, and upon transplantation
they show invasion, intravasation, and
form metastasis. Composite ApcD716/
Aes knockout mice do not carry a Ras
mutation and exhibit intravasation yet
show no malignant tumor progression
and metastasis. In contrast, a mouse
model carrying both an APC and a Ras
mutation [KRAS(V12G)/Apc(+/1638N)]
resembles colorectal cancer in humans,
with tumor invasion, intravasation, and
metastasis (Janssen et al., 2006). Finally,
cis-ApcD716/Smad4mice show local inva-
sion, yet no intravasation, with a signifi-
cant infiltration of immature myeloid cells19, January 18, 2011 ª2011 Elsevier Inc. 7
Figure 1. Model of the Mechanisms by which Aes/Grg5 Modulates Notch Signaling, Cancer
Cell Intravasation, and Metastasis
For details, see text.
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Previewsrequired for tumor invasion (Kitamura
et al., 2007). Thus, the role of Notch may
differ between the various settings, and
other signaling pathways certainly con-8 Cancer Cell 19, January 18, 2011 ª2011 Eltribute as well. On the other hand, Aes/
Grg5 expression inversely correlates
with tumor progression in various cancer
types (Sonoshita et al., 2011), suggestingsevier Inc.that the metastasis suppressor may be
active in many cancer types.
It remains open how the expression of
Aes/Grg5 is repressed in the invasive
cancer cells that are exposed to Notch
signaling activation. A preliminary analysis
by Sonoshita et al. has not revealed any
changes in DNA methylation, and no
mutations in the Aes/Grg5 genes have
been found so far. Thus, for this type of
invasion program, notably in the absence
of EMT, Notch receptor activation by
ligands on neighboring stromal cells and
the concomitant loss of Aes/Grg5 expres-
sion in cancer cells is critical. Conversely,
the lack of Notch signaling in cancer cells,
for example by the lack of access toNotch
ligands on stromal cells or by thepresence
of Aes/Grg5, may reverse the invasion
program, a notion that may set the stage
for the design of novel anti-metastatic
therapy.REFERENCES
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